Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462016 | 0.86 | ALDH1A1 (0.48) | MAPTALDH1A1ATMSCN9AFPR2 | |
| SCHEMBL4318313 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1ATMSCN9AFPR2 | |
| SCHEMBL12303690 | 0.81 | TDP1 (0.49) | P2RY1TDP1MAPTALDH1A1ATM | |
| SCHEMBL11922573 | 0.81 | CFTR (0.51) | P2RY1TDP1MAPTALDH1A1ATM | |
| SCHEMBL27514961 | 0.80 | MAPT (0.51) | MAPTALDH1A1ATMSCN9AFPR2 | |
| SCHEMBL6128279 | 0.80 | TDP1 (0.56) | LMNAP2RY1TDP1MAPTALDH1A1 | |
| SCHEMBL13331058 | 0.80 | PDE10A (0.56) | P2RY1TDP1MAPTALDH1A1KDM4E | |
| SCHEMBL11187255 | 0.79 | ALDH1A1 (0.59) | MAPTALDH1A1ATMSCN9AFPR2 | |
| SCHEMBL8237109 | 0.79 | ALDH1A1 (0.59) | MAPTALDH1A1ATMSCN9AMEN1 | |
| SCHEMBL11684169 | 0.79 | ALDH1A1 (0.51) | P2RY1MAPTALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | LMNA 3634/4885P2RY1 433/4885TDP1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.